Secondary and therapy-related acute myeloid leukaemia: lines of therapy
3 standard-of-care settings across 3 lines and 3 biomarker subgroups. Rows come from the cancer page's standard of care; the grid places each on its line and subgroup.
Advanced, first line
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|---|---|---|---|---|
| Fit | Newly diagnosed, fit for intensive chemotherapy, age 60 to 75 | CPX-351 induction (Study 301) followed by allogeneic transplant in remission; 7+3 where CPX-351 is unavailable. | NCCN Guidelines: Acute Myeloid Leukemia | 92 |
Second line
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|---|---|---|---|---|
| All comers | Consolidation and relapse | Allogeneic transplant is the only curative option; genotype-directed drugs where a FLT3, IDH or KMT2A target exists. | NCCN Guidelines: Acute Myeloid Leukemia | 92 |
Special situations
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|---|---|---|---|---|
| Unfit / older | Newly diagnosed, unfit for intensive chemotherapy | Venetoclax plus azacitidine or decitabine; hypomethylating agent alone for TP53-mutated disease where venetoclax adds little; trials. | NCCN Guidelines: Acute Myeloid Leukemia | 93 |
Lines and subgroups are parsed from the setting text of each standard-of-care row and can misclassify an unusual phrasing; the row’s own setting is always shown. Guideline chips reflect the NCCN category and ESMO-MCBS grade recorded on the cancer page, checked on its stated date. Not medical advice.